Literature DB >> 11096749

Cerebellar Ataxia.

.   

Abstract

There is nothing more discouraging than for a patient to be given a specific diagnosis, then to be told that there is nothing that can be done. Physicians are equally disheartened to see exponential progress being made in the understanding of the pathophysiology of a complex disorder but few direct benefits resulting for their patients. Over the past 5 years, molecular genetic research has completely revolutionized the way in which the progressive cerebellar ataxias are classified and diagnosed, but it has yet to produce effective gene-based, neuroprotective, or neurorestorative therapies. The treatment of cerebellar ataxia remains primarily a neurorehabilitation challenge, employing physical, occupational, speech, and swallowing therapy; adaptive equipment; driver safety training; and nutritional counseling. Modest additional gains are seen with the use of medications that can improve imbalance, incoordination, or dysarthria (amantadine, buspirone, acetazolamide); cerebellar tremor (clonazepam, propranolol); and cerebellar or central vestibular nystagmus (gabapentin, baclofen, clonazepam). Many of the progressive cerebellar syndromes have associated features involving other neurologic systems (eg, spasticity, dystonia or rigidity, resting or rubral tremor, chorea, motor unit weakness or fatigue, autonomic dysfunction, peripheral or posterior column sensory loss, neuropathic pain or cramping, double vision, vision and hearing loss, dementia, and bowel, bladder, and sexual dysfunction), which can impede the treatment of the ataxic symptoms or can worsen with the use of certain drugs. Treatment of the associated features themselves may in turn worsen the ataxia either directly (as side effects of medication) or indirectly (eg, relaxation of lower limb spasticity that was acting as a stabilizer for an ataxic gait). Secondary complications of progressive ataxia can include deconditioning or immobility, weight loss or gain, skin breakdown, recurrent pulmonary and urinary tract infections, aspiration, occult respiratory failure, and obstructive sleep apnea, all of which can be life threatening. Depression in the patient and family members is common. Although no cures exist for most of the causes of cerebellar ataxia and there are as yet no proven ways to protect neurons from premature cell death or to restore neuronal populations that have been lost, symptomatic treatment can greatly improve the quality of life of these patients and prevent complications that could hasten death. Supportive interventions should always be offered-- education about the disease itself, genetic counseling, individual and family counseling, referral to support groups and advocacy groups, and guidance to online resources. Misinformation, fear, depression, hopelessness, isolation, and financial and interpersonal stress can often cause more harm to the patient and caregiver than the ataxia itself.

Entities:  

Year:  2000        PMID: 11096749     DOI: 10.1007/s11940-000-0004-3

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  55 in total

1.  Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors.

Authors:  A Cappelli; M Anzini; S Vomero; L Canullo; L Mennuni; F Makovec; E Doucet; M Hamon; M C Menziani; P G De Benedetti; G Bruni; M R Romeo; G Giorgi; A Donati
Journal:  J Med Chem       Date:  1999-05-06       Impact factor: 7.446

2.  Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients.

Authors:  S L Pullman; P Greene; S Fahn; S F Pedersen
Journal:  Arch Neurol       Date:  1996-07

3.  Double-blind, triple-crossover trial of low doses of oral physostigmine in inherited ataxias.

Authors:  R A Kark; M M Budelli; R Wachsner
Journal:  Neurology       Date:  1981-03       Impact factor: 9.910

4.  Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor.

Authors:  G P Rice; J Lesaux; P Vandervoort; L Macewan; G C Ebers
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

5.  Outcome of pyruvate dehydrogenase deficiency treated with ketogenic diets. Studies in patients with identical mutations.

Authors:  I D Wexler; S G Hemalatha; J McConnell; N R Buist; H H Dahl; S A Berry; S D Cederbaum; M S Patel; D S Kerr
Journal:  Neurology       Date:  1997-12       Impact factor: 9.910

6.  Increased iron in the dentate nucleus of patients with Friedrich's ataxia.

Authors:  D Waldvogel; P van Gelderen; M Hallett
Journal:  Ann Neurol       Date:  1999-07       Impact factor: 10.422

7.  [Efficacy of TRH-T for spinocerebellar degeneration--the relation between clinical features and effect of TRH therapy].

Authors:  M Waragai; K Ogawara; Y Takaya; M Hayashi
Journal:  Rinsho Shinkeigaku       Date:  1997-07

8.  Familial periodic ataxia responsive to flunarizine.

Authors:  M Boel; P Casaer
Journal:  Neuropediatrics       Date:  1988-11       Impact factor: 1.947

9.  Cerebrospinal fluid as a reflector of central cholinergic and amino acid neurotransmitter activity in cerebellar ataxia.

Authors:  B V Manyam; E Giacobini; T N Ferraro; T A Hare
Journal:  Arch Neurol       Date:  1990-11

10.  Hereditary myokymia and paroxysmal ataxia linked to chromosome 12 is responsive to acetazolamide.

Authors:  W J Lubbers; E R Brunt; H Scheffer; M Litt; R Stulp; D L Browne; T W van Weerden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-10       Impact factor: 10.154

View more
  8 in total

1.  Analysis of gait in rats with olivocerebellar lesions and ability of the nicotinic acetylcholine receptor agonist varenicline to attenuate impairments.

Authors:  C S Lambert; R M Philpot; M E Engberg; B E Johns; L Wecker
Journal:  Behav Brain Res       Date:  2015-06-03       Impact factor: 3.332

2.  Therapeutic interventions in the primary hereditary ataxias.

Authors:  Gonzalo J Revuelta; George R Wilmot
Journal:  Curr Treat Options Neurol       Date:  2010-07       Impact factor: 3.598

3.  Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.

Authors:  João Carlos Correia de Sa; Laura Airas; Emmanuel Bartholome; Nikolaos Grigoriadis; Heinrich Mattle; Celia Oreja-Guevara; Jonathan O'Riordan; Finn Sellebjerg; Bruno Stankoff; Karl Vass; Agata Walczak; Heinz Wiendl; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2011-05       Impact factor: 6.570

Review 4.  Spinocerebellar degenerations: an update.

Authors:  Susan L Perlman
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

Review 5.  Movement Disorders in Multiple Sclerosis: An Update.

Authors:  Ritwik Ghosh; Dipayan Roy; Souvik Dubey; Shambaditya Das; Julián Benito-León
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2022-05-04

Review 6.  The spinocerebellar ataxias: order emerges from chaos.

Authors:  Russell L Margolis
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

7.  Aging in individuals with the FMR1 mutation.

Authors:  S Jacquemont; F Farzin; D Hall; M Leehey; F Tassone; L Gane; L Zhang; J Grigsby; T Jardini; F Lewin; E Berry-Kravis; P J Hagerman; R J Hagerman
Journal:  Am J Ment Retard       Date:  2004-03

Review 8.  Fragile X-associated tremor/ataxia syndrome: clinical phenotype, diagnosis, and treatment.

Authors:  Maureen A Leehey
Journal:  J Investig Med       Date:  2009-12       Impact factor: 2.895

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.